← All trials
NCT03714815
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2018
- Primary completion
- Nov 30, 2023
- Completion date
- Nov 30, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ActelionLead sponsor
- Chiltern InternationalCollaborator
- ActelionStudy director
- WorldCare Clinical, LLCCollaborator
- Medidata SolutionsCollaborator
- Frontier Science & Technology Research Foundation, Inc.Collaborator
- CovanceCollaborator
- Almac Clinical Services LLCCollaborator
- ActiGraphCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.